Bellerophon Therapeutics, Inc. (BLPH) financial statements (2021 and earlier)

Company profile

Business Address 184 LIBERTY CORNER ROAD, SUITE 302
WARREN, NJ 07059
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments48101729146
Cash and cash equivalents48101729146
Restricted cash and investments00000 
Other undisclosed current assets00161223
Total current assets:481017362729
Noncurrent Assets
Operating lease, right-of-use asset2 
Property, plant and equipment001112
Restricted cash and investments000000
Other noncurrent assets0  017
Other undisclosed noncurrent assets 2    
Total noncurrent assets:231139
TOTAL ASSETS:501318373038
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities654545
Accounts payable433432
Accrued liabilities221113
Due to related parties    00
Other undisclosed current liabilities434233
Total current liabilities:1088768
Noncurrent Liabilities
Long-term debt and lease obligation1     
Operating lease, liability1 
Other undisclosed noncurrent liabilities(0)27325 
Total noncurrent liabilities:227325 
Total liabilities:12101539128
Stockholders' equity
Stockholders' equity attributable to parent3844(3)1830
Common stock001100
Additional paid in capital253193180176142131
Accumulated other comprehensive loss   (0) (0)
Accumulated deficit(214)(190)(176)(179)(124)(101)
Total stockholders' equity:3844(3)1830
TOTAL LIABILITIES AND EQUITY:501318373038

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues
(Other Operating Income)
     2
Cost of revenue
(Cost of Goods and Services Sold)
(0)     
Gross profit:(0)    2
Operating expenses(26)(17)(28)(25)(24)(48)
Other undisclosed operating income0     
Operating loss:(26)(17)(28)(25)(24)(47)
Nonoperating income (expense)(0)00000
Investment income, nonoperating 00000
Interest and debt expense(0)  (0)  
Loss from continuing operations before equity method investments, income taxes:(27)(17)(28)(25)(24)(46)
Other undisclosed income (loss) from continuing operations before income taxes(0)225(30)(1) 
Loss from continuing operations before income taxes:(27)(15)(3)(55)(24)(46)
Income tax benefit225 0 
Net income (loss) available to common stockholders, diluted:(25)(13)3(55)(24)(46)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(25)(13)3(55)(24)(46)
Other comprehensive income (loss)  0(0)0(0)
Comprehensive income (loss), net of tax, attributable to parent:(25)(13)3(55)(24)(46)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: